Elevance Health, Inc. (Anthem, Inc.) 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 29, 2022, regarding events occurring on April 26, 2022. The registrant, Anthem, Inc. (now Elevance Health, Inc.), reported the closing of a public offering of senior notes.
Key Financial Metrics
The filing details a debt issuance rather than operational performance metrics such as revenue or profit. Key figures include:
- Total Principal Amount Issued: $1.3 billion ($600.0 million in 2032 Notes and $700.0 million in 2052 Notes).
- Net Proceeds: Approximately $1,282.2 million after underwriting discounts and offering expenses.
- Interest Rates: 4.100% for the 2032 Notes and 4.550% for the 2052 Notes.
- Interest Payment Schedule: Semi-annually in arrears on May 15 and November 15, commencing November 15, 2022.
Material Changes
The primary material change is the increase in long-term debt obligations resulting from the new issuance. The company received significant liquidity to be deployed for corporate purposes. The filing does not provide comparative financial data against prior periods as this is a transactional report.
Use of Proceeds and Terms
Management intends to use the net proceeds for working capital and general corporate purposes, including funding acquisitions, repayment of short-term and long-term debt, and repurchasing common stock. The Indenture does not prohibit or limit the incurrence of additional indebtedness.
Redemption Terms: The notes may be redeemed prior to their respective Par Call Dates (February 15, 2032, for the 2032 Notes; November 15, 2051, for the 2052 Notes) at a price equal to the greater of 100% of the principal amount or the present value of remaining payments plus a spread over the Treasury Rate. On or after the Par Call Dates, they may be redeemed at 100% of the principal amount.
Change of Control: If a change of control occurs and the notes are downgraded below investment grade by Moody's, S&P, and Fitch, the company must offer to repurchase the notes at 101% of the principal amount plus accrued interest.
Investor Verification Checklist
- Verify the exact net proceeds of $1,282.2 million against the company's cash flow statement in the next quarterly filing.
- Confirm the allocation of proceeds between debt repayment, acquisitions, and share repurchases in subsequent management commentary.
- Monitor credit rating actions by Moody's, S&P, and Fitch to assess potential triggers for the change of control repurchase offer.
- Review the Underwriting Agreement (Exhibit 1.1) and Indenture (Exhibit 4.1) for detailed covenants and default provisions.